Biophytis SA

09/11/2025 | Press release | Distributed by Public on 09/10/2025 23:09

Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia

11 Sep 2025 07:00 CEST

Subscribe

Issuer

BIOPHYTIS

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_1357435_PR_Detailed_Plan_SARA_VDEF.pdf

Source

Biophytis

Provider

Les Echos

Company Name

BIOPHYTIS

ISIN

FR001400OLP5

Symbol

ALBPS

Market

Euronext Growth

Biophytis SA published this content on September 11, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 11, 2025 at 05:09 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]